This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Celgene Corporation (CELG): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Celgene Corporation (
CELG) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.3%. By the end of trading, Celgene Corporation rose $2.30 (2.4%) to $100.13 on average volume. Throughout the day, 3.6 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.7 million shares. The stock ranged in a price between $97.91-$100.86 after having opened the day at $98.85 as compared to the previous trading day's close of $97.84. Other companies within the Health Care sector that increased today were:
Prima Biomed (
PBMD), up 22%,
Oncolytics Biotech (
ONCY), up 21.9%,
Galectin Therapeutics (
GALT), up 12%, and
Gentiva Health Services (
GTIV), up 11.2%.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $41.41 billion and is part of the drugs industry. The company has a P/E ratio of 19.9, above the S&P 500 P/E ratio of 17.7. Shares are up 24.7% year to date as of the close of trading on Thursday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Celgene Corporation as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.